<html><body><h2>Case: 2166380</h2><h3> CDS Time: 1959-08-08</h3>
<patient name=2166380>
59.0 year old Black_Non-Hispanic Female
<p><b>Lab & Note Entry Values:</b> <table>
<b><tr><td width="200">Lab</td><td width="200">Value</td><td width="200">Date</td></tr></b>
<tr><td width="200">Age</td><td width="200">59</td><td width="200">1970-1-1</td></tr>
<tr><td width="200">Calcium</td><td width="200">9</td><td width="200">1959-4-8</td></tr>
<tr><td width="200">Glucose</td><td width="200">185</td><td width="200">1957-8-13</td></tr>
<tr><td width="200">Potassium</td><td width="200">3</td><td width="200">1959-4-8</td></tr>
<tr><td width="200">LDL_Cholesterol</td><td width="200">164</td><td width="200">1959-4-8</td></tr>
<tr><td width="200">Height</td><td width="200">65</td><td width="200">1959-4-8</td></tr>
<tr><td width="200">HDL_Cholesterol</td><td width="200">32</td><td width="200">1959-4-8</td></tr>
<tr><td width="200">Chloride</td><td width="200">104.0</td><td width="200">1959-4-8</td></tr>
<tr><td width="200">Diastolic_BP</td><td width="200">91</td><td width="200">1959-8-8</td></tr>
<tr><td width="200">BUN</td><td width="200">26</td><td width="200">1959-4-8</td></tr>
<tr><td width="200">Cholesterol</td><td width="200">234</td><td width="200">1959-4-8</td></tr>
<tr><td width="200">HGB</td><td width="200">13</td><td width="200">1959-4-8</td></tr>
<tr><td width="200">HCT</td><td width="200">38</td><td width="200">1959-4-8</td></tr>
<tr><td width="200">Sodium</td><td width="200">139</td><td width="200">1959-4-8</td></tr>
<tr><td width="200">Creatinine</td><td width="200">1.1</td><td width="200">1959-4-8</td></tr>
<tr><td width="200">Weight</td><td width="200">200</td><td width="200">1959-4-8</td></tr>
<tr><td width="200">Triglycerides</td><td width="200">341</td><td width="200">1959-4-8</td></tr>
<tr><td width="200">Total_Cholesterol</td><td width="200">234</td><td width="200">1959-4-8</td></tr>
<tr><td width="200">Pulse</td><td width="200">95</td><td width="200">1959-8-8</td></tr>
<tr><td width="200">PLT</td><td width="200">212</td><td width="200">1959-4-8</td></tr>
<tr><td width="200">WBC</td><td width="200">8</td><td width="200">1959-4-8</td></tr>
<tr><td width="200">Systolic_BP</td><td width="200">130</td><td width="200">1959-8-8</td></tr>
<tr><td width="200">eGFR</td><td width="200">54</td><td width="200">1959-4-8</td></tr>
<tr><td width="200">SGPT</td><td width="200">N/A</td><td width="200">1959-3-11</td></tr>
<tr><td width="200">SGOT</td><td width="200">N/A</td><td width="200">1959-3-11</td></tr>
<tr><td width="200">Total_Bilirubin</td><td width="200">N/A</td><td width="200">1959-3-11</td></tr>
<tr><td width="200">Race</td><td width="200">Black_Non-Hispanic</td><td width="200"></td></tr>
<tr><td width="200">Sex</td><td width="200">Female</td><td width="200"></td></tr>
<tr><td width="200">Tobacco_Use</td><td width="200"></td><td width="200">1959-3-11</td></tr>
<tr><td width="200">smoking</td><td width="200"></td><td width="200">1959-3-11</td></tr>
<tr><td width="200">tobacco use</td><td width="200"></td><td width="200">1959-3-11</td></tr>
<tr><td width="200">Alkaline_phosphatase</td><td width="200">N/A</td><td width="200">1959-3-11</td></tr>
<tr><td width="200">Albumen</td><td width="200">N/A</td><td width="200">1959-3-11</td></tr>
<tr><td width="200">Hyperlipidemia</td><td width="200"></td><td width="200">1959-8-8</td></tr>
<tr><td width="200">Occulusion of cerebral arteries</td><td width="200"></td><td width="200">1959-4-8</td></tr>
<tr><td width="200">Hypertension</td><td width="200"></td><td width="200">1959-4-8</td></tr>
<tr><td width="200">Disorders Lipid Metabolism</td><td width="200"></td><td width="200">1959-8-8</td></tr>
</table>
<p><b>Medications:</b> aspirin(81.0) simvastatin(80.0) atenolol(100.0) lisinopril(40.0) hydrochlorothiazide(25.0) fenofibrate(40.0) lovastatin(80.0) 
<p><b>Problems:</b> <table>
<tr><td width="200"><b>Problem Class</b></td><td width="200"><b>First/Last Dates Reported</b></td><td width="200"></td></tr>
<tr><td width="200">Laboratory_Test_Result_Syndrome</td>
<td width="200"></td>
<td width="200"> hyperglycemia[Glucose(185.0/1957-8-13)]()</td></tr>
<tr> <td width="200"></td>
<td width="200"></td>
<td width="200"> hypokalemia in the past[Potassium(3.1/1959-4-8)]()</td></tr>
<tr><td width="200">Target_Organ_Damage_Clinical_Cardiovascular_Disease</td>
<td width="200"></td>
<td width="200"> TOD/CCD[presence of cerebral vascular dx]()</td></tr>
<tr><td width="200">Dyslipidemia Lab criteria</td>
<td width="200"></td>
<td width="200"> Dyslipidemia Lab criteria[HDL_Cholesterol(32.0/1959-4-8)]()</td></tr>
<tr><td width="200">Using HCTZ; 3.0.<K<3.5</td>
<td width="200"></td>
<td width="200"> Hypokalemia (3.0.<K<3.5mg/dL)[thiazide diuretics being used && Potassium(3.1/1959-4-8) && Potassium(3.1/1959-4-8)]()</td></tr>
<tr><td width="200">Hypokalemia</td>
<td width="200"></td>
<td width="200"> Hypokalemia(<3.5mg/dl)[Potassium(3.1/1959-4-8)]()</td></tr>
<tr><td width="200">Major Cardiovascular Risk Factor</td>
<td width="200"></td>
<td width="200"> Major Cardiovascular Risk Factor[Sex(Female) && Age(59.0/1970-1-1)]()</td></tr>
<tr><td width="200">Dyslipidemia Lab or ICD9</td>
<td width="200"></td>
<td width="200"> Dyslipidemia Lab or ICD9[presence of dyslipidemia lab criteria]()</td></tr>
<tr><td width="200">CKD by eGFR</td>
<td width="200"></td>
<td width="200"> CKD by eGFR[eGFR(54.0/1959-4-8)]()</td></tr>
<tr><td width="200">CKD by eGFR or ICD9 codes</td>
<td width="200"></td>
<td width="200"> CKD[eGFR(54.0/1959-4-8)]()</td></tr>
<tr><td width="200">On meds & Presence of strong contraindication to HCTZ or using bad drug partner</td>
<td width="200"></td>
<td width="200"> Hypertension[Potassium(3.1/1959-4-8) && Antihypertensive_Agents]()</td></tr>
<tr><td width="200">Active prescription for thiazide</td>
<td width="200"></td>
<td width="200"> active prescription for thiazide[presence of thiazide diuretics]()</td></tr>
<tr><td width="200">on >= 1 med</td>
<td width="200"></td>
<td width="200"> Combination therapy for HTN[Antihypertensive_Agents]()</td></tr>
<tr><td width="200">taking >= 2 anti hypertensive meds</td>
<td width="200"></td>
<td width="200"> Combination therapy for HTN[Antihypertensive_Agents]()</td></tr>
<tr><td width="200">On 1 drug and there exists contraindicated drug or a compelling drug not given</td>
<td width="200"></td>
<td width="200"> On 1 drug and there exists contraindicated drug or a compelling drug not given[there exists a compellingly indicated drug that is not already given]()</td></tr>
<tr><td width="200">Absence of Stage D HF</td>
<td width="200"></td>
<td width="200"> Absence of Stage D HF[Not Stage D HF (refractory end stage HF)Stage D HF (refractory end stage HF)]()</td></tr>
<tr><td width="200">High Risk for HF and DM, HTN, or atherosclerotic vascular disease</td>
<td width="200"></td>
<td width="200"> High Risk for HF and DM, HTN, or atherosclerotic vascular disease[Presence of hypertension && Absence of HF]()</td></tr>
<tr><td width="200">CCS-7.4</td>
<td width="200">1959-04-08</td>
<td width="200"> Occulusion of cerebral arteries()</td></tr>
<tr><td width="200">Hypertension_Inclusive</td>
<td width="200">1959-04-08</td>
<td width="200"> Hypertension()</td></tr>
<tr><td width="200">Psychiatric_Diseases</td>
<td width="200">1959-03-11</td>
<td width="200"> Tobacco_Use()</td></tr>
<tr><td width="200">Metabolic&Nutritional_Diseases</td>
<td width="200">1959-08-08</td>
<td width="200"> Disorders Lipid Metabolism()</td></tr>
<tr><td width="200"> <b>Others</b></td>
<td width="200">1959-03-11</td>
<td width="200"> Total_Bilirubin()
<tr> <td width="200"></td>
<td width="200">1959-03-11</td>
<td width="200"> Alkaline_phosphatase()
<tr> <td width="200"></td>
<td width="200">1959-08-08</td>
<td width="200"> Hyperlipidemia()
<tr> <td width="200"></td>
<td width="200"></td>
<td width="200"> Race()
<tr> <td width="200"></td>
<td width="200">1959-03-11</td>
<td width="200"> Albumen()
<tr> <td width="200"></td>
<td width="200">1959-03-11</td>
<td width="200"> tobacco use()
<tr> <td width="200"></td>
<td width="200">1959-03-11</td>
<td width="200"> smoking()
<tr> <td width="200"></td>
<td width="200">1959-03-11</td>
<td width="200"> SGOT()
<tr> <td width="200"></td>
<td width="200"></td>
<td width="200"> Sex()
<tr> <td width="200"></td>
<td width="200">1959-03-11</td>
<td width="200"> SGPT()
</table><p>
</patient>
<h1 align="center">ATHENA Heart Failure Guideline</h1>
<b>Patient classification:</b> <ul>
<li>ATHENA Heart Failure Guideline: true[because <i> Eligibility criteria </i> evaluate to <b>true</b><i>(Not Stage D HF (refractory end stage HF)Stage D HF (refractory end stage HF))</i>]
</ul>
<b>Scenario choice:</b> Stage A HF
<b>Scenario choice:</b> Stage C HF
<p>
<b>Goal:</b> SBP < 140 and DBP < 90(absence of diabetes mellitus)
<p><b>Reached goal?</b> failed(Treatment_Diastolic_BP(91/null))
<p>
<b>Goal:</b> LDL< 130 mg/dL(2+ Risk Factors)
<p><b>Reached goal?</b> failed(LDL_Cholesterol(164.0/1959-4-8))
<p><b>Messages by Types</b>
<ul>
<li><b>Class I</b>
<ul>
<li>In patients at high risk for developing HF, systolic and diastolic hypertension should be controlled in accordance with contemporary
guidelines. (Level of Evidence: A)
<li>In patients at high risk for developing HF, lipid disorders should
be treated in accordance with contemporary guidelines. (Level of
Evidence: A)
<li>Patients at high risk for developing HF should be counseled to avoid behaviors that may increase the risk of HF (e.g., smoking, excessive alcohol consumption, and illicit drug use). (Level of
Evidence: C)
<li>Healthcare providers should perform periodic evaluation for signs
and symptoms of HF in patients at high risk for developing HF.
(Level of Evidence: C)
</ul>
<li><b>Class III</b>
<ul>
<li>Routine use of nutritional supplements solely to prevent the development of structural heart disease should not be recommended for patients at high risk for developing HF. (Level of
Evidence: C)
</ul>
</ul>
<p><b>Action Choices</b>
<ul>
<li><b>Stage A messages</b><br>
<ul>
<li><b>Hypertension control <font color=FF0000>preferred</font></b>(rule in criterion<i> BP not under control</i> evaluate to <b> true</b> because <i>BP not under controlTreatment_Diastolic_BP(91/null)</i>)])
In patients at high risk for developing HF, systolic and diastolic hypertension should be controlled in accordance with contemporary
guidelines. (Level of Evidence: A)
<li><b>Lipid disorder control <font color=FF0000>preferred</font></b>(rule in criterion<i> Lipid not under control</i> evaluate to <b> true</b> because <i>Lipid not under controlLDL_Cholesterol(164.0/1959-4-8)</i>)])
In patients at high risk for developing HF, lipid disorders should
be treated in accordance with contemporary guidelines. (Level of
Evidence: A)
<li><b>behavior control <font color=FF0000>preferred</font></b>(rule in criterion<i> true</i> evaluate to <b> true</i>)])
Patients at high risk for developing HF should be counseled to avoid behaviors that may increase the risk of HF (e.g., smoking, excessive alcohol consumption, and illicit drug use). (Level of
Evidence: C)
<li><b>Periodic evaluation <font color=FF0000>preferred</font></b>(rule in criterion<i> true</i> evaluate to <b> true</i>)])
Healthcare providers should perform periodic evaluation for signs
and symptoms of HF in patients at high risk for developing HF.
(Level of Evidence: C)
<li><b>not use nutritional supplements <font color=FF0000>preferred</font></b>(rule in criterion<i> true</i> evaluate to <b> true</i>)])
Routine use of nutritional supplements solely to prevent the development of structural heart disease should not be recommended for patients at high risk for developing HF. (Level of
Evidence: C)
</ul>
<li><b> </b><br>
<ul>
<li><b>stage A drug choices <font color=FF0000>preferred</font></b>(strict rule-in condition<i> DM or HTN or atherosclerotic vascular disease</i> evaluate to <b> true</b> because <i>Presence of hypertension</i>)])

</ul>
</ul>
<b>Considerations for adding drug: </b><ul><li>ARB<ul><li>Relative indications:  High Risk for HF and DM, HTN, or atherosclerotic vascular disease(High Risk for HF and DM, HTN, or atherosclerotic vascular disease[Presence of hypertension && Absence of HF]) <li>preference: preferred</ul><li>Ace_Inhibitor(Captopril, Lisinopril, Enalapril)<ul><li>Already being used<li>Relative indications:  High Risk for HF and DM, HTN, or atherosclerotic vascular disease(High Risk for HF and DM, HTN, or atherosclerotic vascular disease[Presence of hypertension && Absence of HF]) <li>preference: ruled out</ul></ul></body></html>